Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome
ImmunityBio, a clinical-stage immunotherapy company, today announced the opening of a clinical trial to study […]
Ventoux Biosciences Launches to Transform Disease Management for Fibrotic Disease
Ventoux Biosciences, a privately held specialty pharmaceutical company, has launched with a mission to deliver […]
Ciliatech Raises €3.5M in Series A Funding
Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, […]
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy
Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called […]
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
ImmunoGen, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of […]
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
OKYO Pharma, an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease […]
Fractyl Health Announces the Initiation of a Global Registry Study of the Revita System™ in Patients With Inadequately Controlled Type 2 Diabetes (T2D)
Fractyl Health, a commercial-stage organ-editing metabolic therapeutics company focused on pioneering new approaches for the […]
Bridge Biotherapeutics Receives FDA Authorization to Proceed with the First-in-Human Study of BBT-207
Bridge Biotherapeutics, a clinical-stage biotech company based in South Korea and Cambridge that is advancing novel drugs for […]
Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes
The research results of a Daewoong Pharmaceutical SGLT-2 inhibitor new drug for diabetes, ‘Envlo’, have been […]
CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)
CymaBay Therapeutics, a biopharmaceutical company focused on developing and providing access to innovative therapies for […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more